ObjectiveTo observe the effect of SSY-B2 on microglial cells in rats after bilateral fornix/fimbria transection.MethodsMale adult SD rats were divided randomly into 6 groups as sham group,model group,positive control agent piracetam group, SSY-B2 low(1.5g crude drug/kg), medium(3g crude drug/kg)and high dosage (6g crude drug/kg)groups. Half to 1 hour before operation, water or drugs were fed introgastrically to each group respectively and continued for 6 weeks.The tissues of brain was gained and the immunoreactive products of BS-I B4 (Isolectin B4 from Bandeiraea Simplifolia, a marker for microglia) in the perilesion area was measured using immunohistochemical methods.ResultsThe number of microglia of the sham and model groups was (30.3±21.8) and (114.5±102.3) respectively, P<0.05. That of three different dosage of SSY-B2 groups was(249.7±149.4), (252.0±191.7)and (244.2±154.9), P<0.05 for each group compared with the model group.ConclusionMicroglia number in the perilesion area can be increased by SSY-B2, which may contribute to the nerve repair and functional improvement after injury.

OBJECTIVETo evaluate the measurement of Samarium-153 ethylenediaminetetramethylene phosphonic acid ((153)Sm-EDTMP) bone uptake rate using whole-body scintigraphy and analyze the relationship between bone uptake rate and therapeutic effect.

METHODSSixty-six patients with painful bony metastases from prostate (n = 15), lung (n = 20), breast (n= 18), nasopharyngeal carcinoma (NPC) (n=5), colon (n=2), kidney (n=2) and unknown cause (n=4) carcinoma were examined with whole-body scintigraphy 10 min and 5 h post administration of (153)Sm-EDTMP. Bone uptake rate was then calculated. (1 ) Complete response (CR): disappearance of > 2 metastases, Karnofsky Performance Score (KPS) increase > 20, moderate or complete remission of bone pain 7 d post injection of (153)Sm-EDTMP. (2) Partial response (PR): disappearance of 1-2 metastases, KPS increase 10-20, moderate remission of bone pain in 3 wk. (3) Non-response (NR): no disappearance or shrinkage of metastases, KPS increase < 10, no or slight remission of bone pain.

RESULTSThe range of bone uptake rate in 66 patients was 31 .9% - 86.6% (mean = 56. 0%). The bone uptake rate in the CR group (17 cases, 25.7%), PR group (24 cases, 36.4%), and NR group (25 cases, 37.9%) was 52.4% - 86.6% (mean = 68.7%), 43.7% - 70.4% (mean = 58.3%), and 31.9%- 51 .5% (mean = 41 . 0%) respectively. Statistical analysis showed that there was a significant difference between the CR and PR groups ( t = 4.258, P = 0.001 ) as well as between PR and NR groups ( t = 8.48,P = 0.001 ).

CONCLUSIONSUsing a simple and reliable whole-body scintigraphic technique to calculate prospectively the bone uptake rate, we have, for the first time in China, reported the relationship between bone uptake rate and therapeutic effect. This allows nuclear medicine physicians to calculate a safe and effective dose of (153)Sm-EDTMPin individual patients to palliate bone cancer pain without myelotoxicity.

Bone Neoplasms ; drug therapy ; secondary ; Bone and Bones ; metabolism ; Female ; Humans ; Male ; Organometallic Compounds ; pharmacokinetics ; therapeutic use ; Organophosphorus Compounds ; pharmacokinetics ; therapeutic use